Management consensus guideline for hepatocellular carcinoma

2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. Methods: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention. Results: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation. Conclusion: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.

Original languageEnglish
Pages (from-to)381-403
Number of pages23
JournalJournal of the Formosan Medical Association
Volume117
Issue number5
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Liver Neoplasms
Taiwan
Hepatocellular Carcinoma
Consensus
Guidelines
Radiotherapy
Physicians
Drug Therapy
Mortality
Liver
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Local ablation group ; Surveillance group ; Diagnosis group ; Staging group ; Surgery group ; TACE/TARE/HAI group ; Target therapy/systemic therapy group ; Radiotherapy group ; Prevention group ; Drafting group. / Management consensus guideline for hepatocellular carcinoma : 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. In: Journal of the Formosan Medical Association. 2018 ; Vol. 117, No. 5. pp. 381-403.
@article{91feb138e66e40de8c10c62052925306,
title = "Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan",
abstract = "Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. Methods: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention. Results: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation. Conclusion: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.",
author = "{Local ablation group} and {Surveillance group} and {Diagnosis group} and {Staging group} and {Surgery group} and {TACE/TARE/HAI group} and {Target therapy/systemic therapy group} and {Radiotherapy group} and {Prevention group} and {Drafting group} and Lu, {Sheng Nan} and Wang, {Jing Houng} and Su, {Chien Wei} and Wang, {Tsang En} and Dai, {Chia Yen} and Chen, {Chien Hung} and Chen, {Ran Chou} and Yang, {Sien Sing} and Hung, {Chien Fu} and Huang, {Shiu Feng} and Liao, {Li Ying} and Huo, {The Ia} and Wu, {Cheng Chung} and Lee, {Po Huang} and Ting, {Chin Tsung} and Lee, {Wei Chen} and Chau, {Gar Yang} and Wang, {Chih Chi} and Lee, {King The} and Huang, {Yi Hsiang} and Ho, {Ming Chih} and Lin, {Shi Ming} and Huang, {Guan Tarn} and Chen, {Kuan Yang} and Xi-Zhang Lin and Hwang, {Jen I.} and Chiou, {Yi You} and Wang, {Chung Kwe} and Hu, {Jui Ting} and Chen, {Shinn Cherng} and Liang, {Po Chin} and Lee, {Rheun Chuan} and Wu, {Ding Kwo} and Lin, {Cheng Yao} and Lin, {Chen Chun} and Cheng, {Ann Lii} and Chiun Hsu and Yee Chao and Chen, {Li Tzong} and Wang, {Po Ming} and Wang, {Po Ming} and Hong, {Ji Hong} and Hsu, {Hsuan Chih} and Chen, {Shang Wen} and Leung, {Stephen Wan} and Cheng, {Jason Chia Hsien} and Wu, {Jaw Ching} and Wu, {Chun Ying} and Hsu, {Yao Chun} and Hsu, {Chao Wei}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.jfma.2017.09.007",
language = "English",
volume = "117",
pages = "381--403",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "5",

}

Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group & Drafting group 2018, 'Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan', Journal of the Formosan Medical Association, vol. 117, no. 5, pp. 381-403. https://doi.org/10.1016/j.jfma.2017.09.007

Management consensus guideline for hepatocellular carcinoma : 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. / Local ablation group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group.

In: Journal of the Formosan Medical Association, Vol. 117, No. 5, 01.05.2018, p. 381-403.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management consensus guideline for hepatocellular carcinoma

T2 - 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

AU - Local ablation group

AU - Surveillance group

AU - Diagnosis group

AU - Staging group

AU - Surgery group

AU - TACE/TARE/HAI group

AU - Target therapy/systemic therapy group

AU - Radiotherapy group

AU - Prevention group

AU - Drafting group

AU - Lu, Sheng Nan

AU - Wang, Jing Houng

AU - Su, Chien Wei

AU - Wang, Tsang En

AU - Dai, Chia Yen

AU - Chen, Chien Hung

AU - Chen, Ran Chou

AU - Yang, Sien Sing

AU - Hung, Chien Fu

AU - Huang, Shiu Feng

AU - Liao, Li Ying

AU - Huo, The Ia

AU - Wu, Cheng Chung

AU - Lee, Po Huang

AU - Ting, Chin Tsung

AU - Lee, Wei Chen

AU - Chau, Gar Yang

AU - Wang, Chih Chi

AU - Lee, King The

AU - Huang, Yi Hsiang

AU - Ho, Ming Chih

AU - Lin, Shi Ming

AU - Huang, Guan Tarn

AU - Chen, Kuan Yang

AU - Lin, Xi-Zhang

AU - Hwang, Jen I.

AU - Chiou, Yi You

AU - Wang, Chung Kwe

AU - Hu, Jui Ting

AU - Chen, Shinn Cherng

AU - Liang, Po Chin

AU - Lee, Rheun Chuan

AU - Wu, Ding Kwo

AU - Lin, Cheng Yao

AU - Lin, Chen Chun

AU - Cheng, Ann Lii

AU - Hsu, Chiun

AU - Chao, Yee

AU - Chen, Li Tzong

AU - Wang, Po Ming

AU - Wang, Po Ming

AU - Hong, Ji Hong

AU - Hsu, Hsuan Chih

AU - Chen, Shang Wen

AU - Leung, Stephen Wan

AU - Cheng, Jason Chia Hsien

AU - Wu, Jaw Ching

AU - Wu, Chun Ying

AU - Hsu, Yao Chun

AU - Hsu, Chao Wei

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. Methods: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention. Results: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation. Conclusion: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.

AB - Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. Methods: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention. Results: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation. Conclusion: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.

UR - http://www.scopus.com/inward/record.url?scp=85032017775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032017775&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2017.09.007

DO - 10.1016/j.jfma.2017.09.007

M3 - Article

VL - 117

SP - 381

EP - 403

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 5

ER -